Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Segment Reporting (Tables)

9 Months Ended

Apr. 30, 2024

The following financial information represents the operating results of the reportable segments of the Company:

	Products			Corporate & Other			Consolidated
Revenues	$	8,022		$	—		$	8,022

Operating costs and expenses:
Cost of revenues		4,289			—			4,289
Research and development		595			10			605
Selling, general and administrative		2,881			1,598			4,479
Legal and related expenses		—			692			692
Total operating costs and expenses		7,765			2,300			10,065

Operating income (loss)		257			(2,300	)		(2,043	)

Other income (expense)
Interest		37			689			726
Change in fair value of convertible debentures		—			(384	)		(384	)
Other		(31	)		125			94
Foreign exchange loss		(524	)		—			(524	)
Loss before taxes	$	(261	)	$	(1,870	)	$	(2,131	)

Depreciation and amortization included above	$	162		$	175		$	337

Share-based compensation included above:
Selling, general and administrative		32			167			199
Cost of sales		8			—			8
Total	$	40		$	167		$	207

Capital expenditures	$	123		$	20		$	143

	Products			Corporate & Other			Consolidated
Revenues	$	7,485		$	—		$	7,485

Operating costs and expenses:
Cost of revenues		4,476			—			4,476
Research and development		872			12			884
Selling, general and administrative		3,069			3,143			6,212
Legal and related expenses		19			4,246			4,265
Total operating costs and expenses		8,436			7,401			15,837

Operating loss		(951	)		(7,401	)		(8,352	)

Other income (expense)
Interest		30			(66	)		(36	)
Other		2			142			144
Foreign exchange gain		347			—			347
Loss before taxes	$	(572	)	$	(7,325	)	$	(7,897	)

Depreciation and amortization included above	$	182		$	93		$	275

Share-based compensation included above:
Selling, general and administrative		20			462			482
Cost of sales		6			—			6
Total	$	26		$	462		$	488

Capital expenditures	$	331		$	282		$	613

	Products			Corporate & Other			Consolidated
Revenues	$	24,381		$	—		$	24,381

Operating costs and expenses:
Cost of revenues		12,969			—			12,969
Research and development		2,012			23			2,035
Selling, general and administrative		9,266			7,284			16,550
Legal and related expenses		51			2,476			2,527
Total operating costs and expenses		24,298			9,783			34,081

Operating income (loss)		83			(9,783	)		(9,700	)

Other income (expense)
Interest		104			2,491			2,595
Change in fair value of convertible debentures		—			(1,095	)		(1,095	)
Other		(28	)		401			373
Foreign exchange loss		(842	)		—			(842	)
Loss before taxes	$	(683	)	$	(7,986	)	$	(8,669	)

Depreciation and amortization included above	$	500		$	374		$	874

Share-based compensation included above:
Selling, general and administrative		97			1,421			1,518
Cost of sales		25			—			25
Total	$	122		$	1,421		$	1,543

Capital expenditures	$	369		$	53		$	422

	Products			Corporate & Other			Consolidated
Revenues	$	22,102		$	—		$	22,102

Operating costs and expenses:
Cost of revenues		13,681			—			13,681
Research and development		2,675			33			2,708
Selling, general and administrative		8,989			8,089			17,078
Legal and related expenses		55			6,105			6,160
Total operating costs and expenses		25,400			14,227			39,627

Operating loss		(3,298	)		(14,227	)		(17,525	)

Other income (expense)
Interest		84			15			99
Other		6			256			262
Foreign exchange gain		1,022			—			1,022
Income (loss) before taxes	$	(2,186	)	$	(13,956	)	$	(16,142	)

Depreciation and amortization included above	$	518		$	267		$	785

Share-based compensation included above:
Selling, general and administrative		60			1,211			1,271
Cost of sales		17			—			17
Total	$	77		$	1,211		$	1,288

Capital expenditures	$	1,268		$	506		$	1,774